Hunter disease is an X-linked lysosomal storage disorder characterized by progressive storage of glycosaminoglycans (GAGs) and multi-organ impairment. The central nervous system (CNS) is involved in at least 50% of cases. Since 2006, the enzymatic replacement therapy (ERT) is available but with no effect on the cognitive impairment, as the present formulation does not cross the blood-brain barrier. Here we report the outcome of 17 Hunter patients treated in a single center. Most of them (11) started ERT in 2006, 3 had started it earlier in 2004, enrolled in the phase III trial, and 3 after 2006, as soon as the diagnosis was made. The liver and spleen sizes and urinary GAGs significantly decreased and normalized throughout the treatment. Heart parameters improved, in particular the left ventricular mass index/m(2) decreased significantly. Amelioration of hearing was seen in many patients. Joint range of motion improved in all patients. However, no improvement on respiratory function, eye, skeletal and CNS disease was found. The developmental quotient of patients with a CNS involvement showed a fast decline. These patients were no more testable after 6 years of age and, albeit the benefits drawn from ERT, their quality of life worsened throughout the years. The whole group of patients showed a consistent residual disease burden mainly represented by persistent skeletal disease and frequent need of surgery. This study suggests that early diagnosis and treatment and other different therapies which are able to cross the blood-brain barrier, might in the future improve the MPS II outcome.
Keywords: 6MWT, Six minute walking test; BAER, Brainstem auditory evoked responses; CNS, Central nervous system; EF, Ejection fraction; ENT, Ear nose and throat; ERT; ERT, Enzyme replacement therapy; Enzymatic replacement therapy; GAGs, Glycosaminoglycans; HAQ, Health Assessment Questionnaire; Hunter disease; Hunter syndrome; I2S, Iduronate-2-sulfatase; Idursulfase; JROM, Joint range of motion; LVM/LVMI, Left ventricular mass/left-ventricular mass index; MDCT, Multidetector computed tomography; MPS II; MPS II, Mucopolysaccharidosis type II; MPS, Mucopolysaccharidosis; MRI, Magnetic resonance imaging; Mucopolysaccharidosis type II; QoL, Quality of Life; UAI, Upper airway infections.